Multivariate Analysis of Several Molecular Markers and Clinicopathological Features in Postoperative Prognosis of Hepatocellular Carcinoma

Zuo, Qiang; Huang, Hui; Shi, Min; Zhang, Futing; Sun, Jia; Bin, Jianping; Liao, Yulin; Liao, Wangjun

doi:10.1002/ar.21531

Cited by 30 publications

(34 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As high XB130 expression was significantly worse than that of the patients with low XB130 expression. In hepatocellular carcinoma [14], positive expression rate of XB130 in HCC was 75.0%, but XB130 is not associated with the postoperative prognosis of patients with HCC. In human esophageal squamous cell carcinoma (ESCC) [11], 71.2% of the patients expressed XB130 in the nuclei and/or cytoplasm of the ESCC cells.…”

Section: Discussionmentioning

confidence: 89%

XB130 expression in human osteosarcoma: a clinical and experimental study

Wang¹,

Ruiguo²,

Liu³

et al. 2015

View full text Add to dashboard Cite

Identifying prognostic factors for osteosarcoma (OS) aids in the selection of patients who require more aggres sive management. XB130 is a newly characterized adaptor protein that was reported to be a prognostic factor of certain tumor types. However, the association between XB130 expression and the prognosis of OS remains unknown. In the present study, we investigated the association between XB130 expression and clinicopathologic features and prognosis in patients suffering OS, and further investigated its potential role on OS cells in vitro and vivo. A retrospective immunohistochemical study of XB130 was performed on archival formalin-fixed paraffin-embedded specimens from 60 pairs of osteosarcoma and noncancerous bone tissues, and compared the expression of XB130 with clinicopathological parameters. We then investigate the effect of XB130 sliencing on invasion in vitro and lung metastasis in vivo of the human OS cell line. Immunohistochemical assays revealed that XB130 expression in OS tissues was significantly higher than that in corresponding noncancerous bone tissues (P = 0.001). In addition, high XB130 expression more frequently occurred in OS tissues with advanced clinical stage (P = 0.002) and positive distant metastasis (P = 0.001). Moreover, OS patients with high XB130 expression had significantly shorter overall survival and disease-free survival (both P < 0.001) when compared with patients with the low expression of XB130. The univariate analysis and multivariate analysis shown that high XB130 expression and distant metastasis were the independent poor prognostic factor.We showed that XB130 depletion by RNA interference inhibited invasion of XB130-rich U2OS cells in vitro and lung metastasis in vivo. This is the first study to reveal that XB130 overexpression may be related to the prediction of metastasis potency and poor prognosis for OS patients, suggesting that XB130 may serve as a prognostic marker for the optimization of clinical treatments. Furthermore, XB130 is the potential molecular target for OS therapy.

show abstract

Section: Discussionmentioning

confidence: 89%

XB130 expression in human osteosarcoma: a clinical and experimental study

Wang¹,

Ruiguo²,

Liu³

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Hoffmann et al demonstrated that the mRNA of Ras, MEK, ERK and MAPK was overexpressed in 33, 40, 50 and 50% of HCC patients, respectively (23). Similarly, H-ras has been found to be activated in ~93.8% of HCC cases (24). A study further showed that the expression Raf and its downstream genes, MEK and ERK, were upregulated in samples of hepatocirrhosis and HCC (25).…”

Section: Ras/raf/mek/erk Pathway Activation In Hccmentioning

confidence: 95%

“…As a result, this may lead to activating oncogenic Ras in HCC (38). In addition to the mutation or deletion of B-Raf, codon 12 of the K-Ras and N-Ras genes is also mutated or deleted in HCC, accounting for 4.69 and 41.37% of cases (24,38,39). Challen et al found that mutations of the K-ras and N-ras genes in codon 61 occurs in 5.3 and 15.8% of HCC cases (40).…”

Section: Ras/raf/mek/erk Pathway Activation In Hccmentioning

confidence: 99%

Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma

2017

View full text Add to dashboard Cite

Abstract. Although the biological basis of hepatocellular carcinoma (HCC) remains unclear, effective treatments and improvement of the survival rate remain worthwhile research goals. Abnormal protein signaling pathways contributing to uncontrolled cell proliferation, differentiation, survival and apoptosis are biomarkers of the carcinogenic process. Certain mutated components or overexpression of the rat sarcoma virus (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway are increasingly being studied in HCC carcinogenesis. The present review addresses the effect of the Ras/Raf/MEK/ERK signaling pathway on the pathogenesis of HCC, and provides an update on the preclinical and clinical development of various inhibitors targeting this core signaling pathway, which include various Ras inhibitors, Raf inhibitors and MEK inhibitors for HCC.

show abstract

“…For example, a multivariate analysis of biomarkers and clinical features in postoperative hepatocellular carcinoma (HCC) carried out by Zuo et al (53) showed that the positive expression rates of the XB130 protein in Chinese patients with HCC is high (75.0%), but its expression level is not associated with postoperative prognosis (P=0.848). Shiozaki et al (54) explored the possible role of XB130 in cell cycle progression of esophageal squamous cell carcinoma (ESCC) cells and its expression and effects on the prognosis of patients with ESCC.…”

Section: Xb130 In Cancermentioning

confidence: 99%

XB130: A novel adaptor protein in cancer signal transduction

Zhang

et al. 2016

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Adaptor proteins are functional proteins that contain two or more protein-binding modules to link signaling proteins together, which affect cell growth and shape and have no enzymatic activity. The actin filament-associated protein (AFAP) family is an important member of the adaptor proteins, including AFAP1, AFAP1L1 and AFAP1L2/XB130. AFAP1 and AFAP1L1 share certain common characteristics and function as an actin-binding protein and a cSrc-activating protein. XB130 exhibits certain unique features in structure and function. The mRNA of XB130 is expressed in human spleen, thyroid, kidney, brain, lung, pancreas, liver, colon and stomach, and the most prominent disease associated with XB130 is cancer. XB130 has a controversial effect on cancer. Studies have shown that XB130 can promote cancer progression and downregulation of XB130-reduced growth of tumors derived from certain cell lines. A higher mRNA level of XB130 was shown to be associated with a better survival in non-small cell lung cancer. Previous studies have shown that XB130 can regulate cell growth, migration and invasion and possibly has the effect through the cAMP-cSrc-phosphoinositide 3-kinase/Akt pathway. Except for cancer, XB130 is also associated with other pathological or physiological procedures, such as airway repair and regeneration.

show abstract

Multivariate Analysis of Several Molecular Markers and Clinicopathological Features in Postoperative Prognosis of Hepatocellular Carcinoma

Cited by 30 publications

References 44 publications

XB130 expression in human osteosarcoma: a clinical and experimental study

XB130 expression in human osteosarcoma: a clinical and experimental study

Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma

XB130: A novel adaptor protein in cancer signal transduction

Contact Info

Product

Resources

About